Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Combined targeting of HER-2 and HER-3 represents a promising therapeutic strategy in colorectal cancer

Fig. 4

Comparison of anti-HER-2/HER-3 monotherapy and a combination with 5-FU and oxaliplatin. Displayed are the respective EC50 24 h (black bar charts), 48 h (red bar charts), and 72 h (blue bar charts) after treatment. Compared to monotherapy, the combination of T-DM1 (a), lapatinib (b), and afatinib (c) with 5-FU and oxaliplatin mediated stronger effects only in LS513 and LS1034, but not in SW837. Not shown are the bar charts for trastuzumab and pertuzumab, as they were not time- and dose-dependent

Back to article page